NRP1 and pancreatic neoplasm: Other agents such as SEMA3a conjugated with a lytic peptide have been proposed as therapeutic agents against PDAC.72 While these hybrid lytic peptides demonstrated cytotoxic effects against NRP‐1‐positive pancreatic cancer cells, they did not affect the normal NRP‐1‐positive cell types.